Oncolytics Biotech (NASDAQ:ONCY) Insider Purchases $25,456.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) insider Andrew Aromando purchased 29,600 shares of the stock in a transaction dated Wednesday, February 11th. The shares were acquired at an average price of $0.86 per share, with a total value of $25,456.00. Following the completion of the acquisition, the insider owned 55,100 shares in the company, valued at approximately $47,386. This trade represents a 116.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oncolytics Biotech Price Performance

Shares of ONCY stock opened at $0.83 on Friday. Oncolytics Biotech Inc. has a 1-year low of $0.33 and a 1-year high of $1.51. The firm has a market cap of $88.60 million, a PE ratio of -2.98 and a beta of 0.99. The company has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. Sell-side analysts anticipate that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright boosted their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a report on Monday, November 17th. Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Finally, Zacks Research raised Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Oncolytics Biotech presently has an average rating of “Moderate Buy” and an average target price of $6.25.

Hedge Funds Weigh In On Oncolytics Biotech

Large investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new stake in Oncolytics Biotech in the third quarter valued at $535,000. Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech during the fourth quarter worth approximately $63,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the fourth quarter worth approximately $44,000. Ground Swell Capital LLC acquired a new position in Oncolytics Biotech in the fourth quarter valued at approximately $30,000. Finally, Seeds Investor LLC increased its stake in Oncolytics Biotech by 17.8% in the second quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after purchasing an additional 33,826 shares during the last quarter. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.